Granulocytes

Onchilles Pharma Raises $7 Million Series A to Advance Drug Candidates to Activate Newly Discovered Broad-Acting Anticancer Pathway

Retrieved on: 
Thursday, June 10, 2021
Health, Science, Pharmaceutical, Research, Oncology, Branches of biology, Articles, Business, Cell biology, Granulocytes, Neutrophil, Phagocytes, Entrepreneurship, LYZZ Capital, Onchilles Pharma, LYZZ CAPITAL, ONCHILLES PHARMA

Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicagos Startup Investment Fund.

Key Points: 
  • Onchilles Pharma announced today a $7 Million Series A financing from LYZZ Capital and includes a $500,000 investment from the University of Chicagos Startup Investment Fund.
  • This financing will support proof-of-concept preclinical studies as well as exploration of this novel pathway for additional drug targets.
  • The University of Chicagos Polsky Center for Entrepreneurship and Innovation manages the licensed intellectual property and negotiated the exclusive license with Onchilles Pharma.
  • Onchilles Pharma was founded on breakthrough research of a novel neutrophil pathway that when activated selectively and comprehensively kills cancer cells.

Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

Retrieved on: 
Friday, February 26, 2021
Branches of biology, Life sciences, Biology, Cell biology, Granulocytes, Mast cell, Biopharmaceutical, Anaphylaxis

"We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics.

Key Points: 
  • "We are delighted to expand this strategic alliance with NC State and our Scientific Advisory Board member, Dr. Glenn Cruse," saidRobb Knie, CEO of Hoth Therapeutics.
  • "We believe that the HT-KIT pathway is a promising novel target for combating both mast cell-derived cancers and mast cell-mediated anaphylaxis.
  • Hoth also intends to pursue the anaphylaxis indication for HT-KIT in parallel to cancer treatment and HT-004 development.
  • Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs.

Tezepelumab NAVIGATOR Phase III Trial Met Primary Endpoint of a Statistically Significant and Clinically Meaningful Reduction in Exacerbations in a Broad Population of Patients With Severe Asthma

Retrieved on: 
Tuesday, November 10, 2020
Health, Other Health, Managed care, Pharmaceutical, Cardiology, Biotechnology, Branches of biology, Health, Medical specialties, Clinical trials, Medical statistics, Cell biology, Eosinophil, Granulocytes, Asthma, Clinical endpoint

AstraZeneca and Amgen today announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma.

Key Points: 
  • AstraZeneca and Amgen today announced positive results from the NAVIGATOR Phase III trial for the potential new medicine tezepelumab in patients with severe, uncontrolled asthma.
  • In the subgroup of patients with baseline eosinophil counts less than 300 cells per microliter the trial also met the primary endpoint, with tezepelumab demonstrating a statistically significant and clinically meaningful reduction in AAER.
  • The trial population included approximately equal proportions of patients with high ( 300 cells/L) and low (
  • Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma (DESTINATION) [Online].

Allakos Reports Third Quarter 2020 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 9, 2020
Cell biology, Eosinophil, Granulocytes

REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter endedSeptember 30, 2020 and provided an update of its ongoing development activities.

Key Points: 
  • REDWOOD CITY, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) for the treatment of eosinophil and mast cell-related diseases, today reported financial results for the third quarter endedSeptember 30, 2020 and provided an update of its ongoing development activities.
  • Announced positive safety, pharmacokinetic, and pharmacodynamic results from a randomized, double-blind, placebo-controlled Phase 1 study of subcutaneous lirentelimab in healthy volunteers.
  • The results showed that subcutaneously administered lirentelimab had bioavailibity of 63% and suppressed eosinophils for up to 85 days.
  • These documents contain and identify important factors that could cause the actual results forAllakosto differ materially from those contained in Allakos forward-looking statements.

Hofseth Biocare ASA: New study highlights the potential of OmeGo® as a prophylactic therapy for Asthma and COPD

Retrieved on: 
Tuesday, September 1, 2020
Cell biology, Eosinophil, Granulocytes

This in-vitro study investigated the prophylactic effect of HBCs enzymatically extracted salmon oil, OmeGo, as a proxy for eating fresh whole oily fish, on eosinophil function using allergic human peripheral blood eosinophils.

Key Points: 
  • This in-vitro study investigated the prophylactic effect of HBCs enzymatically extracted salmon oil, OmeGo, as a proxy for eating fresh whole oily fish, on eosinophil function using allergic human peripheral blood eosinophils.
  • The eosinophil inhibition with OmeGo was comparable to APOA-IV (active control) and markedly better than processed salmon oil.
  • Pre-clinical work with OmeGo targeting eosinophil effector function is ongoing with guinea pig dosing studies and house dust mite studies.
  • Hofseth BioCare's headquarters are in lesund, Norway with branches in Oslo, London, Zrich, Chicago, Menlo Park and Tokyo.

Celldex Announces Acceptance of CDX-0159 Late-Breaking Poster Presentation with Voice Over at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress 2020

Retrieved on: 
Wednesday, May 6, 2020
Branches of biology, Biology, Cell biology, Tyrosine kinase receptors, Immunology, Granulocytes, Glycoproteins, Mast cell, Receptor tyrosine kinase, Degranulation, Tyrosine kinase, Antibody

CDX-0159 is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity.

Key Points: 
  • CDX-0159 is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity.
  • The KIT receptor tyrosine kinase is expressed in a variety of cells, including mast cells.
  • In certain inflammatory diseases, such as chronic urticarias, mast cell degranulation plays a central role in the onset and progression of the disease.
  • You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release.

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 DDW Annual Meeting

Retrieved on: 
Tuesday, April 21, 2020
Branches of biology, Cell biology, Granulocytes, DDW, Eosinophil, SIGLEC, Immunoglobulin E, Poster session, Mast cell

REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting.

Key Points: 
  • REDWOOD CITY, Calif., April 21, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (Nasdaq: ALLK), a biotechnology company developing antolimab (AK002) for the treatment of eosinophil and mast cell related diseases, today announced the acceptance of four oral and three poster presentations at the upcoming Digestive Disease Week (DDW) Annual Meeting.
  • The presentations will take place during the DDW Annual Meeting being held virtually from May 2 to 5, 2020.
  • Access to all accepted abstracts, ePosters and ePapers will be available starting May 2 from the DDW ePosters and ePapers website .
  • The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.

Allakos Announces Multiple Presentations Related to Eosinophil and Mast Cell-Driven Diseases at the 2020 AAAAI Annual Meeting

Retrieved on: 
Monday, February 24, 2020
Branches of biology, Medical specialties, Biology, Immunology, Cell signaling, Immune system disorders, Immune system, Eosinophil, Granulocytes, Esophagitis, Antibody, Effector cell

Diagnosis of Eosinophilic Esophagitis/March 14, 9:45-10:45 am

Key Points: 
  • Diagnosis of Eosinophilic Esophagitis/March 14, 9:45-10:45 am
    Following the presentations, the posters will be available on the Allakos website.
  • Allakosis a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases.
  • The Companys lead antibody, antolimab (AK002), targets Siglec-8, an inhibitory receptor selectively expressed on human mast cells and eosinophils.
  • Antolimab (AK002) has been shown to inhibit mast cells and deplete eosinophils.